Grimes & Company’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.4M | Sell |
137,963
-10,716
| -7% | -$1.41M | 0.38% | 54 |
|
|
2026
Q1 | $20.7M | Sell |
148,679
-1,689
| -1% | -$237K | 0.57% | 37 |
|
|
2025
Q4 | $18.5M | Sell |
150,368
-9,777
| -6% | -$1.19M | 0.44% | 46 |
|
|
2025
Q3 | $17.8M | Buy |
160,145
+2,872
| +2% | +$326K | 0.44% | 46 |
|
|
2025
Q2 | $17.4M | Sell |
157,273
-6,346
| -4% | -$675K | 0.47% | 46 |
|
|
2025
Q1 | $18.3M | Sell |
163,619
-15,810
| -9% | -$1.63M | 0.57% | 42 |
|
|
2024
Q4 | $16.6M | Buy |
179,429
+1,535
| +0.9% | +$138K | 0.48% | 49 |
|
|
2024
Q3 | $14.9M | Sell |
177,894
-14,135
| -7% | -$1.08M | 0.4% | 57 |
|
|
2024
Q2 | $13.2M | Buy |
192,029
+174,623
| +1,003% | +$11.7M | 0.39% | 59 |
|
|
2024
Q1 | $1.27M | Buy |
17,406
+362
| +2% | +$27.8K | 0.04% | 163 |
|
|
2023
Q4 | $1.38M | Buy |
17,044
+99
| +0.6% | +$7.7K | 0.05% | 153 |
|
|
2023
Q3 | $1.27M | Buy |
16,945
+145
| +0.9% | +$11.2K | 0.05% | 143 |
|
|
2023
Q2 | $1.29M | Buy |
16,800
+18
| +0.1% | +$1.44K | 0.05% | 143 |
|
|
2023
Q1 | $1.39M | Sell |
16,782
-250
| -1% | -$20.7K | 0.06% | 130 |
|
|
2022
Q4 | $1.46M | Sell |
17,032
-29
| -0.2% | -$2.3K | 0.06% | 135 |
|
|
2022
Q3 | $1.05M | Buy |
17,061
+103
| +0.6% | +$6.5K | 0.06% | 137 |
|
|
2022
Q2 | $1.05M | Sell |
16,958
-27
| -0.2% | -$1.67K | 0.05% | 143 |
|
|
2022
Q1 | $1.01M | Buy |
16,985
+325
| +2% | +$20.8K | 0.05% | 157 |
|
|
2021
Q4 | $1.21M | Buy |
16,660
+60
| +0.4% | +$4.13K | 0.06% | 148 |
|
|
2021
Q3 | $1.16M | Buy |
16,600
+11
| +0.1% | +$773 | 0.05% | 145 |
|
|
2021
Q2 | $1.14M | Buy |
16,589
+11
| +0.1% | +$735 | 0.05% | 146 |
|
|
2021
Q1 | $1.07M | Buy |
16,578
+2,215
| +15% | +$143K | 0.05% | 143 |
|
|
2020
Q4 | $837K | Sell |
14,363
-167
| -1% | -$10.1K | 0.04% | 150 |
|
|
2020
Q3 | $918K | Sell |
14,530
-37
| -0.3% | -$2.57K | 0.06% | 132 |
|
|
2020
Q2 | $1.12M | Sell |
14,567
-236
| -2% | -$18.1K | 0.08% | 120 |
|
|
2020
Q1 | $1.11M | Buy |
14,803
+339
| +2% | +$23.4K | 0.1% | 111 |
|
|
2019
Q4 | $940K | Buy |
14,464
+1,850
| +15% | +$120K | 0.06% | 135 |
|
|
2019
Q3 | $800K | Sell |
12,614
-174
| -1% | -$11.4K | 0.06% | 139 |
|
|
2019
Q2 | $864K | Sell |
12,788
-432
| -3% | -$28.4K | 0.07% | 128 |
|
|
2019
Q1 | $859K | Sell |
13,220
-365
| -3% | -$24.3K | 0.07% | 121 |
|
|
2018
Q4 | $850K | Buy |
13,585
+9
| +0.1% | +$629 | 0.08% | 114 |
|
|
2018
Q3 | $1.05M | Sell |
13,576
-155
| -1% | -$11.7K | 0.08% | 116 |
|
|
2018
Q2 | $973K | Sell |
13,731
-1,576
| -10% | -$111K | 0.09% | 123 |
|
|
2018
Q1 | $1.15M | Buy |
15,307
+11,985
| +361% | +$953K | 0.11% | 112 |
|
|
2017
Q4 | $238K | Buy |
+3,322
| New | +$252K | 0.02% | 192 |
|
|
2017
Q3 | – | Sell |
-3,193
| Closed | -$226K | – | 207 |
|
|
2017
Q2 | $226K | Buy |
+3,193
| New | +$212K | 0.03% | 187 |
|
|
2017
Q1 | – | Sell |
-3,023
| Closed | -$216K | – | 205 |
|
|
2016
Q4 | $216K | Sell |
3,023
-425
| -12% | -$31.6K | 0.03% | 185 |
|
|
2016
Q3 | $273K | Sell |
3,448
-1,002
| -23% | -$81.4K | 0.04% | 164 |
|
|
2016
Q2 | $371K | Buy |
4,450
+568
| +15% | +$50.4K | 0.05% | 146 |
|
|
2016
Q1 | $357K | Sell |
3,882
-4,096
| -51% | -$369K | 0.05% | 141 |
|
|
2015
Q4 | $807K | Buy |
7,978
+770
| +11% | +$80.1K | 0.11% | 106 |
|
|
2015
Q3 | $708K | Buy |
7,208
+436
| +6% | +$48.4K | 0.09% | 107 |
|
|
2015
Q2 | $793K | Buy |
6,772
+4,595
| +211% | +$502K | 0.11% | 98 |
|
|
2015
Q1 | $214K | Buy |
+2,177
| New | +$221K | 0.05% | 146 |
|
Other funds holding GILD
Grimes & Company's GILD Position: Q2 2026 in Review
Grimes & Company reduced its Gilead Sciences (GILD) stake by 7.2% in Q2 2026, selling an estimated $1.41M and leaving 137,963 shares worth $17.4M. The position accounts for 0.38% of the portfolio, ranked #54.
Grimes & Company first reported a position in GILD in Q1 2015 and has held it in 44 quarters since. The position peaked at $20.7M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Grimes & Company held 137,963 shares of Gilead Sciences worth $17.4M as of Q2 2026.
- Grimes & Company sold 10,716 Gilead Sciences shares in Q2 2026, an estimated $1.41M.
- Gilead Sciences made up 0.38% of Grimes & Company's portfolio in Q2 2026, its #54 holding.
- Grimes & Company first reported a position in Gilead Sciences in Q1 2015 and has held it in 44 quarters since.
- Grimes & Company's Gilead Sciences position peaked at $20.7M in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.